Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Roopa Achuri

Physician Assistant Neenah, WI Physician Assistant

NPI 1225531635 CMS profile 10797216

200 Theda Clark Medical Plz Ste 240, Neenah, WI 54956

Open in the dashboard

General payments

$9,816

410 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roopa Achuri of Neenah, WI is reported in the CMS Open Payments database as having received $9,816 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,209 125
2024 General $2,985 132
2023 General $2,246 88
2022 General $1,111 55
2021 General $265 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roopa Achuri
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Roopa Achuri were reported at $3,209. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Roopa Achuri Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $265 $132 $37–$438 $132
2022 $1,111 $155 $48–$522 $149
2023 $2,246 $167 $52–$557 $160
2024 $2,985 $178 $55–$600 $164
2025 $3,209 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,770 78 payments
  2. Janssen Biotech, Inc. $1,052 37 payments
  3. GlaxoSmithKline, LLC. $1,046 18 payments
  4. AbbVie, Inc. $841 56 payments
  5. Pfizer Inc. $670 31 payments
  6. Novartis Pharmaceuticals Corporation $661 30 payments
  7. Radius Health, Inc. $439 16 payments
  8. UCB, Inc. $400 20 payments
  9. Lilly USA, LLC $389 14 payments
  10. AstraZeneca Pharmaceuticals LP $293 9 payments
  11. Other $2,257 101 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,568 406 payments
  2. Education $248 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $984 34 payments
  2. BENLYSTA $921 17 payments
  3. RINVOQ $721 50 payments
  4. Enbrel $718 34 payments
  5. XELJANZ $633 30 payments
  6. EVENITY $441 20 payments
  7. TAVNEOS $392 18 payments
  8. TALTZ $389 14 payments
  9. Otezla $374 22 payments
  10. COSENTYX $361 20 payments
  11. Other $4,969 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,568

Median for Physician Assistant: 241

Drug cost

$1,106,406

Median for Physician Assistant: $4,110

Branded share of claims

19.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 37 $231,386
Kevzara Sarilumab Brand 36 $166,672
Rinvoq Upadacitinib Brand 13 $115,074
Enbrel Sureclick Etanercept Brand 12 $102,990
Orencia Clickject Abatacept Brand 16 $100,938
Xeljanz Tofacitinib Citrate Brand 17 $97,452
Cimzia (2 Pack) Certolizumab Pegol Brand 13 $76,580
Enbrel Etanercept Brand 11 $72,794
Orencia Abatacept Brand 12 $67,166
Prolia Denosumab Brand 11 $19,251

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$1,194,261

Of which drugs: $1,046,065

Medicare patients

706

Average age 75

Services billed

123,637

587 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Osteoporosis 60%
Depression 27%
Ischemic heart disease 23%
Chronic kidney disease 22%
Diabetes 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 145 12,660 $258,913
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 28 58,000 $210,366
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 16 4,275 $144,934
Injection, romosozumab-aqqg, 1 mg J3111 Office 24 14,280 $122,674
Injection, tocilizumab, 1 mg J3262 Office 11 24,960 $117,532
Injection, zoledronic acid, 1 mg J3489 Office 58 290 $1,461
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,217
Vaccine for influenza for injection into muscle 90653 Office 14 14 $1,145
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 135 648 $465

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XELJANZ
  • PFIZER INC. $266
$266 17 —
RINVOQ
  • AbbVie, Inc. $234
$234 13 —
TALTZ
  • Lilly USA, LLC $226
$226 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $193
$193 — —
TREMFYA
  • Janssen Biotech, Inc. $178
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record